Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -99.97% is 26% below its 5-year average of -79.52%, around the middle of its 5-year range (-151.20%–-26.38%).
17.06% above its 12-month average of -120.54%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -36.36%.
RETURN ON ASSETS (ROA)
-99.97%
RETURN ON ASSETS (ROA) AVG TTM
-120.54%
RETURN ON ASSETS (ROA) AVG 3Y
-89.96%
RETURN ON ASSETS (ROA) AVG 5Y
-79.52%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+17.06%
CURRENT VS 3Y AVG
-11.12%
CURRENT VS 5Y AVG
-25.71%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-271.64%
vs the sector median at left
Femasys Inc.
Market Cap
$6.10M
Return on Assets (ROA)
-99.97%
TTM Avg
-120.54%
3Y Avg
-89.96%
5Y Avg
-79.52%
Market Cap
$6.10M
Return on Assets (ROA)
-81.62%
TTM Avg
-81.33%
3Y Avg
-106.24%
5Y Avg
-102.80%
Market Cap
$6.09M
Return on Assets (ROA)
83.82%
TTM Avg
-0.56%
3Y Avg
-31.49%
5Y Avg
-28.41%
Market Cap
$6.19M
Return on Assets (ROA)
-54.95%
TTM Avg
-72.19%
3Y Avg
-72.80%
5Y Avg
-69.14%
Market Cap
$6.46M
Return on Assets (ROA)
-55.85%
TTM Avg
-69.75%
3Y Avg
-63.38%
5Y Avg
-59.39%
Market Cap
$6.44M
Return on Assets (ROA)
-426.88%
TTM Avg
-139.62%
3Y Avg
-270.47%
5Y Avg
-207.15%
Market Cap
$5.59M
Return on Assets (ROA)
-68.33%
TTM Avg
-234.58%
3Y Avg
-196.81%
5Y Avg
-171.01%
Market Cap
$5.54M
Return on Assets (ROA)
-104.10%
TTM Avg
-116.11%
3Y Avg
-102.15%
5Y Avg
-84.67%
Market Cap
$6.72M
Return on Assets (ROA)
-71.23%
TTM Avg
-61.08%
3Y Avg
-51.04%
5Y Avg
-61.11%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Femasys Inc. (FEMY) | $6.10M | -99.97% | -120.54% | -89.96% | -79.52% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | -81.62% | -81.33% | -106.24% | -102.80% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | 83.82% | -0.56% | -31.49% | -28.41% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.19M | -54.95% | -72.19% | -72.80% | -69.14% |
| Biomerica, Inc. (BMRA)vs › | $6.46M | -55.85% | -69.75% | -63.38% | -59.39% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | -426.88% | -139.62% | -270.47% | -207.15% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.59M | -68.33% | -234.58% | -196.81% | -171.01% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.54M | -104.10% | -116.11% | -102.15% | -84.67% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -71.23% | -61.08% | -51.04% | -61.11% |
| Aclarion, Inc. (ACON)vs › | $6.80M | -50.98% | -191.11% | -206.10% | -240.87% |
ROA
-100.0%
ROE
-304.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -89.88% |
| 2024-12-31 | -151.20% |
| 2023-12-31 | -51.33% |
| 2022-12-31 | -67.44% |
| 2021-12-31 | -26.38% |
| 2020-12-31 | -90.91% |
| 2019-12-31 | -89.13% |
